Scholar Rock Holding Corporation, trading on NASDAQ under the symbol SRRK, is a biopharmaceutical company focused on developing innovative treatments for serious diseases. The company has garnered attention from analysts and investors alike, with a consensus recommendation of "Buy" from sixteen brokerages. This includes one sell recommendation, eleven buy recommendations, and four strong buy recommendations.
On January 7, 2026, Michael Yee from UBS set a price target of $60 for SRRK, suggesting a potential price increase of approximately 45.24% from its current price of $41.31. This optimistic outlook is supported by other analysts, with an average 12-month price target of $48.9. Barclays has also increased its price target from $45 to $52, maintaining an "overweight" rating.
Cantor Fitzgerald reiterated an "overweight" rating for Scholar Rock on December 11th, while Wolfe Research began coverage on November 18th with an "outperform" rating and a price target of $42. Despite the stock's recent 3.39% decrease, these ratings indicate strong confidence in the company's future performance.
The stock has experienced fluctuations, with a low of $41.19 and a high of $43.06 in recent trading. Over the past year, SRRK has reached a high of $48.28 and a low of $22.71. The company's market capitalization is approximately $4.21 billion, with a trading volume of 707,076 shares, reflecting active investor interest.
